Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

With a Phase III readout imminent for Deciphera's kinase switch control inhibitor ripretinib in GIST, Zai Lab has obtained the compound's rights in Greater China, adding to a planned gastric cancer franchise it has built via a handful of deals.

Zai Lab Ltd. (NASDAQ:ZLAB) CFO Billy Cho told BioCentury the company will seek to obtain ripretinib's local approval to treat gastrointestinal stromal tumors (GIST) in a second-line and a fourth-line setting. The inhibitor of c-Kit and PDGFRA is in Phase

Read the full 794 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE